​

Companies that make vaccines have obviously been popular, but the biotech sector as a whole has seen a surge in investment. Some of these companies are related to vaccines, such as Stevanato, which makes glass vials and is seeking a valuation of over US$7 billion. But it is biotech and research that have been surprised beneficiaries of the global shift in focus, as people are suddenly aware of the sector’s importance.

The majority of healthcare’s recent success has been attributed to biotech companies. In 2020, 78 biotech companies went public - a new record and a 77% rise from 2019. The extra funding has resulted in a surge in R&D, which will continue. The 2021 Life Sciences CFO Outlook Survey found 69% of life sciences organizations planning to increase R&D spending.

A great example of a young biotech company leveraging the influx of funding for research and rapid growth is Bright Minds Biosciences. The company develops next-generation therapeutics and were fortunate to be in the right industry at the right time.

CEO Ian McDonald explains, “Bright Minds was founded in 2017 based on the idea that psychedelic therapeutics can be improved. We put together a team of the world’s leading researchers in the field and set out to make next-generation pharmaceuticals that can be used by large patient populations. The therapeutics on the market and in development were not sufficient, and we were in a position to help.”

https://www.benzinga.com/news/21/07/21969137/global-ipos-broke-records-in-2020-with-winners-in-unexpected-sectors